Literature DB >> 28403903

Feasibility and safety of whole-body vibration therapy in intensive care patients.

Peter Alter1, Tobias Boeselt2, Christoph Nell2, Marc Spielmanns3, Klaus Kenn4, A Rembert Koczulla5.   

Abstract

Entities:  

Mesh:

Year:  2017        PMID: 28403903      PMCID: PMC5390344          DOI: 10.1186/s13054-017-1669-2

Source DB:  PubMed          Journal:  Crit Care        ISSN: 1364-8535            Impact factor:   9.097


× No keyword cloud information.
We read with great interest the article by Wollersheim and colleagues who examined whole-body vibration (WBV) in intensive care unit patients [1]. Hemodynamic characteristics were monitored during WBV application. The study underscores previous findings showing that no significant changes in heart rate, blood pressure, or oxygen saturation occurred during WBV in critically ill patients, nor when compared with healthy controls [2]. In the present study, unconscious sedated patients received WBV in a flat supine position without any changes in body position, except flexion of the hips and knees. The method raises the question whether enough load was applied to the vibrating plate to lead to a sufficient neuromuscular response. To increase this load and involve neuromuscular recruiting, it might be helpful to modify the patient’s position by inclination of the bed to approximately 20° to 25° degrees of tilt [2]. It is suggested that this would involve a greater muscular proportion of the whole body. In conscious patients, additional training effects may be achieved by the use of a (yet customized) vibrating dumbbell for the upper extremities. Since the recent method is preliminary in the current setting, potential effects on muscle function and morphology should be assessed in further studies [3]. A short-term response could be detected, e.g., by electromyography [2]. Longer-term effects involve muscular morphology, e.g., hypertrophy, which can be assessed by sonography-based morphometry [4]. It remains debatable whether catecholamines influenced the findings in the present study, since no controls were examined [5]. In summary, WBV, if applicable in conjunction with a vibrating dumbbell, appears safe and feasible in early rehabilitation. Potential beneficial long-term effects remain to be shown.
  4 in total

1.  Effects of whole-body vibration exercise on the endocrine system of healthy men.

Authors:  C Di Loreto; A Ranchelli; P Lucidi; G Murdolo; N Parlanti; A De Cicco; O Tsarpela; G Annino; C Bosco; F Santeusanio; G B Bolli; P De Feo
Journal:  J Endocrinol Invest       Date:  2004-04       Impact factor: 4.256

2.  Different Training-Induced Skeletal Muscle Adaptations in COPD Patients with and without Alpha-1 Antitrypsin Deficiency.

Authors:  Inga Jarosch; Sebastian Gehlert; Daniel Jacko; Rembert Andreas Koczulla; Marion Wencker; Tobias Welte; Wilhelm Bloch; Sabina Janciauskiene; Klaus Kenn
Journal:  Respiration       Date:  2016-09-30       Impact factor: 3.580

3.  Whole-body vibration therapy in intensive care patients: A feasibility and safety study.

Authors:  Tobias Boeselt; Christoph Nell; Katahrina Kehr; Angélique Holland; Marc Dresel; Timm Greulich; Björn Tackenberg; Klaus Kenn; Johannes Boeder; Benjamin Klapdor; Andreas Kirschbaum; Claus Vogelmeier; Peter Alter; Andreas Rembert Koczulla
Journal:  J Rehabil Med       Date:  2016-03       Impact factor: 2.912

4.  Whole-body vibration to prevent intensive care unit-acquired weakness: safety, feasibility, and metabolic response.

Authors:  Tobias Wollersheim; Kurt Haas; Stefan Wolf; Knut Mai; Claudia Spies; Elisabeth Steinhagen-Thiessen; Klaus-D Wernecke; Joachim Spranger; Steffen Weber-Carstens
Journal:  Crit Care       Date:  2017-01-09       Impact factor: 9.097

  4 in total
  1 in total

1.  Effect of vibration therapy on physical function in critically ill adults (VTICIA trial): protocol for a single-blinded randomised controlled trial.

Authors:  Nobuto Nakanishi; Satoshi Doi; Yoshimi Kawahara; Mie Shiraishi; Jun Oto
Journal:  BMJ Open       Date:  2021-03-02       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.